Efficacy of atypical v. typical antipsychotics in the treatment of early psychosis: meta-analysis

The British Journal of Psychiatry : the Journal of Mental Science
Nicolas A CrossleyPaddy Power

Abstract

There is an ongoing debate about the use of atypical antipsychotics as a first-line treatment for first-episode psychosis. To examine the evidence base for this recommendation. Meta-analyses of randomised controlled trials in the early phase of psychosis, looking at long-term discontinuation rates, short-term symptom changes, weight gain and extrapyramidal side-effects. Trials were identified using a combination of electronic (Cochrane Central, EMBASE, MEDLINE and PsycINFO) and manual searches. Fifteen randomised controlled trials with a total of 2522 participants were included. No significant differences between atypical and typical drugs were found for discontinuation rates (odds ratio (OR) = 0.7, 95% CI 0.4 to 1.2) or effect on symptoms (standardised mean difference (SMD) = -0.1, 95% CI -0.2 to 0.02). Participants on atypical antipsychotics gained 2.1 kg (95% CI 0.1 to 4.1) more weight than those on typicals, whereas those on typicals experienced more extrapyramidal side-effects (SMD = -0.4, 95% CI -0.5 to -0.2). There was no evidence for differences in efficacy between atypical and typical antipsychotics, but there was a clear difference in the side-effect profile.

References

Sep 1, 1986·Controlled Clinical Trials·R DerSimonian, N Laird
Oct 6, 1997·BMJ : British Medical Journal·M EggerC Minder
Jan 19, 1999·The American Journal of Psychiatry·T M SangerG D Tollefson
Apr 18, 2003·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Jeffrey A LiebermanRobert M Hamer
Jun 11, 2003·Archives of General Psychiatry·John M DavisIra D Glick
Oct 30, 2003·The Cochrane Database of Systematic Reviews·C RummelS Leucht
May 3, 2005·The American Journal of Psychiatry·Nina SchoolerUNKNOWN Early Psychosis Global Working Group
Jul 12, 2005·Schizophrenia Bulletin·Delbert G RobinsonJohn M Kane
Aug 2, 2005·The British Journal of Psychiatry : the Journal of Mental Science·Sylvia ParkStephen B Soumerai
Sep 21, 2005·The New England Journal of Medicine·Jeffrey A LiebermanUNKNOWN Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Investigators
Apr 6, 2006·The American Journal of Psychiatry·Robin EmsleyRossella Medori
Jul 11, 2006·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Stefan LeuchtRolf R Engel
Aug 5, 2006·Schizophrenia Research·A I GreenUNKNOWN HGDH Study Group
Nov 17, 2006·The Journal of Clinical Psychiatry·Benedicto Crespo-FacorroJosé Luis Vázquez-Barquero
Dec 8, 2006·The American Journal of Psychiatry·Robert A RosenheckUNKNOWN CATIE Study Investigators
Apr 28, 2007·The Australian and New Zealand Journal of Psychiatry·Warrick J BrewerChristos Pantelis
May 4, 2007·Progress in Neuro-psychopharmacology & Biological Psychiatry·Shin-Min LeeMao-Hsiung Yen
Dec 21, 2007·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Juan R BustilloJohn Lauriello
Mar 4, 2008·The British Journal of Psychiatry : the Journal of Mental Science·Shôn Lewis, Jeffrey Lieberman
Jun 3, 2008·The British Journal of Psychiatry : the Journal of Mental Science·M SmithK Ismail
Oct 2, 2008·The British Journal of Psychiatry : the Journal of Mental Science·Matthew LargeTim Slade
Dec 9, 2008·Lancet·Peter Tyrer, Tim Kendall
Jun 6, 2009·Nature Reviews. Neurology·Russell L Margolis

❮ Previous
Next ❯

Citations

Apr 23, 2013·Frontiers of Medicine·Qingqing XuShengying Qin
May 11, 2011·International Journal of Obesity : Journal of the International Association for the Study of Obesity·J Zheng, F L Greenway
Oct 23, 2010·Metabolic Syndrome and Related Disorders·Jude U Ohaeri, Abayomi O Akanji
Jan 24, 2013·Therapeutic Advances in Chronic Disease·Erik Johnsen, Rune A Kroken
Mar 1, 2012·International Journal of Clinical Pharmacology and Therapeutics·Michael Bewernitz, Hartmut Derendorf
Dec 12, 2012·Indian Journal of Psychiatry·Amresh ShrivastavaNilesh Shah
Jul 6, 2014·BioMed Research International·Nevena DivacNatasa Cerovac
May 23, 2013·Clinical Psychology Review·Brandon A Gaudiano, Ivan W Miller
Dec 15, 2015·International Clinical Psychopharmacology·Suresh DurgamIstván Laszlovszky
Jan 16, 2016·Molecular Neurobiology·Marc Fakhoury
Nov 26, 2015·Clinical Psychopharmacology and Neuroscience : the Official Scientific Journal of the Korean College of Neuropsychopharmacology·Daeyoung RohChan-Hyung Kim
Oct 29, 2015·The International Journal of Neuropsychopharmacology·Miquel BioqueUNKNOWN PEPs GROUP
Jul 15, 2015·Fish Physiology and Biochemistry·Kelly Juliana SeibtCarla Denise Bonan
Jun 16, 2012·International Journal of Mental Health Nursing·Ellie BrownSimon Whitfield
Mar 15, 2013·Epilepsia·Naoto AdachiPerminder Sachdev
Dec 23, 2011·Advances in Urology·Erik JohnsenHugo A Jørgensen
Sep 26, 2015·Early Intervention in Psychiatry·Georgia L StevensJacqueline Zummo
Apr 14, 2016·Canadian Journal of Kidney Health and Disease·Sonja GandhiAmit X Garg
Aug 4, 2015·Journal of Psychiatric and Mental Health Nursing·D Bressington, J White
Jun 15, 2011·Behavioural Brain Research·Kelly Juliana SeibtCarla Denise Bonan
Nov 21, 2014·International Journal of Psychiatry in Clinical Practice·Francesco PietriniAndrea Ballerini
Jul 27, 2010·Schizophrenia Research·Rajiv TandonMatcheri S Keshavan
Sep 12, 2015·The Lancet. Psychiatry·Patrick D McGorryIan B Hickie
Feb 23, 2013·Clinical Psychopharmacology and Neuroscience : the Official Scientific Journal of the Korean College of Neuropsychopharmacology·Rebecca SchennachHans-Jürgen Möller
Mar 1, 2012·Psychiatry Research·Koichiro FujimakiShigeto Yamawaki
Feb 26, 2016·Journal of Psychiatric and Mental Health Nursing·R Gray, K Deane
Jun 9, 2016·Journal of Psychiatric Research·Marc Fakhoury
Oct 30, 2016·Biochemical and Biophysical Research Communications·Minoru AsadaHidenori Suzuki
Apr 4, 2015·International Journal of Psychiatry in Medicine·Carlo PiccinniFabrizio de Ponti
Feb 18, 2012·Journal of Psychopharmacology·Mark TaylorJari Tiihonen
Feb 22, 2017·Molecular Psychiatry·A Busquets-GarciaG Marsicano
Feb 5, 2011·Journal of Psychopharmacology·Thomas R E Barnes, UNKNOWN Schizophrenia Consensus Group of British Association for Psychopharmacology
Jul 16, 2017·Journal of Basic and Clinical Physiology and Pharmacology·Patrick AmoatengAlexander K Nyarko

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antipsychotic Drugs

Antipsychotic drugs are a class of medication primarily used to manage psychosis (including delusions, hallucinations, paranoia or disordered thought), principally in schizophrenia and bipolar disorder. Discover the latest research on antipsychotic drugs here

Antipsychotic-Induced Weight Gain

Antipsychotic-induced weight gain (aiwg) is a common adverse effect of this treatment, particularly with second-generation antipsychotics, and it is a major health problem around the world. Here are the latest discoveries pertaining to AIWG.